Spinosyn formulations for treatment of Demodex-induced ocular and facial conditions
Inventors
Santos, Carlos • CHEN, IUAN-BOR • MORAN, JOSUE
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11254701-B2
Publication Date
2022-02-22
Expiration Date
Abstract
The present invention concerns materials and methods for treating an ocular Demodex mite infestation of an eye of a human or animal subject, or for treating a condition of the eye or skin associated with ocular Demodex mite infestation, the method comprising topically administering a composition comprising one or more spinosyn compounds to the ocular surface (conjunctiva and/or cornea) or other anatomical structure of the eye, or to an area adjacent the eye.
Core Innovation
The invention relates to methods for treating a condition, sign, or symptom of the eye or skin associated with ocular Demodex mite infestation in a human or animal subject. The method includes topically administering a miticidally effective amount of a composition comprising one or more spinosyn compounds to one or more anatomical sites of the eye selected from eyelid, eyelid margin, eyelash, eyelash follicles, eyebrow, eyebrow follicles, or the corner of the eye.
The disclosure identifies ocular and facial conditions and signs associated with Demodex infestation and links the topical administration to treating these conditions, signs, and symptoms. Documented examples include Demodex-induced blepharitis, Demodex-induced ocular rosacea, Demodex-induced facial rosacea, dry eye, meibomian gland dysfunction, chalazion, hordeolum, follicular inflammation, non-specific facial dermatitis, infiltrative keratoconjunctivitis, nodular scar deposition, corneal neovascularization, itching, burning, foreign body sensation, and crusting and redness of lid margin, as well as blurry vision and eyelash misalignment-related conditions.
The compositions are based on spinosyn compounds, including spinosyn A and spinosyn D, and include pharmaceutically acceptable salts. The disclosure describes topical compositions in solutions, suspensions, creams, ointments, and emulsions, along with ophthalmically or dermatologically acceptable bases and optional accessory components.
The system further includes embodiments for delivery and use, including topical application to ocular surface and adjacent periocular structures and container/applicator/kit embodiments. The disclosure also includes detecting Demodex presence, including in vivo confocal microscopy and molecular detection using PCR and real-time PCR, with immunoassay and target biomolecule mentions.
Claims Coverage
The document contains one independent claim covering a topical therapeutic method for Demodex-associated eye/skin conditions. The inventive scope centers on administering a miticidally effective composition containing one or more spinosyn compounds to specific ocular anatomical sites.
Topical administration of miticidally effective spinosyn composition
A method for treating a condition, sign, or symptom of the eye or skin associated with ocular Demodex mite infestation, comprising topically administering a miticidally effective amount of a composition comprising one or more spinosyn compounds to one or more anatomical sites of the eye having the condition, sign, or symptom.
Selected ocular anatomical sites for treatment
The one or more anatomical sites are selected from an eyelid, eyelid margin, eyelash, eyelash follicles, eyebrow, eyebrow follicles, or corner of the eye.
Claim coverage is anchored in a topical method that applies a miticidally effective composition containing one or more spinosyn compounds to specified ocular anatomical sites to treat an eye or skin condition, sign, or symptom associated with ocular Demodex mite infestation.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treating ocular Demodex mite infestation-associated eye or skin conditions, signs, or symptoms in a human or animal subject by topical administration to ocular anatomical sites.
Treating Demodex-related ocular conditions and signs listed in the disclosure, including Demodex-induced blepharitis, Demodex-induced ocular rosacea, Demodex-induced facial rosacea, dry eye, meibomian gland dysfunction, chalazion, hordeolum, follicular inflammation, non-specific facial dermatitis, infiltrative keratoconjunctivitis, nodular scar deposition, corneal neovascularization, itching, burning, foreign body sensation, crusting and redness of lid margin, and blurry vision.
Treating eyelash misalignment-related conditions including eyelash trichiasis and eyelash madarosis.
Interested in licensing this patent?